Impact of Replacing Low Dose Cyclophosphamide with Fludarabine in Children with Acute Myeloid Leukemia Undergoing Transplantation During First Complete Remission

Basit Öğe Kaydı
dc.contributor.authorUygun, Vedat
dc.contributor.authorKarasu, Gulsun
dc.contributor.authorYalcin, Koray
dc.contributor.authorOzturkmen, Seda
dc.contributor.authorDaloglu, Hayriye
dc.contributor.authorCelen, Safiye Suna
dc.contributor.authorHazar, Volkan
dc.date.accessioned2024-05-19T14:40:00Z
dc.date.available2024-05-19T14:40:00Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBusulfan (BU)-based myeloablative conditioning is a standard conditioning regimen for children with AML; however, it is not clear yet which combination of cyclophosphamide (CY) and fludarabine (FLU) is most effective. We performed a study to compare the results of BUCY120 and BU-FLU in pediatric patients with AML in CR1 undergoing allo-HSCT from matched sibling donors. With the combination of BU, 15 patients were given 120 mg/kg of CY, and 12 patients were given 150 mg/m2 of FLU, respectively, in the condition regimen. Patients treated with BUFLU relapsed less than those treated with BUCY120 (p= 0.03). Moreover, these patients engrafted platelets earlier than the BUCY120 administered patients (p= 0.03). The frequency of complications in both groups was comparable. There was no significant difference in survival analysis between the groups. BUFLU has a low toxicity profile, making it a reasonable choice for children with AML in CR1 with low risk and a lower relapse frequency compared to BUCY120.en_US
dc.identifier.doi10.4999/uhod.237292
dc.identifier.endpage211en_US
dc.identifier.issn1306-133X
dc.identifier.issue4en_US
dc.identifier.startpage206en_US
dc.identifier.urihttps://doi.org10.4999/uhod.237292
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4890
dc.identifier.volume33en_US
dc.identifier.wosWOS:001157848500006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectChildrenen_US
dc.subjectAmlen_US
dc.subjectConditioningen_US
dc.subjectFludarabineen_US
dc.subjectLeukemiaen_US
dc.titleImpact of Replacing Low Dose Cyclophosphamide with Fludarabine in Children with Acute Myeloid Leukemia Undergoing Transplantation During First Complete Remissionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu